Jak2 inhibition deactivates Lyn kinase through the SET-PP2A-SHP1 pathway, causing apoptosis in drug-resistant cells from chronic myelogenous leukemia patients

Oncogene

Volumn 28, Issue 14, 2009, Pages 1669-1681

  Samanta, A K ^a   Chakraborty, S N ^a   Wang, Y ^a   Kantarjian, H ^a   Sun, X ^a   Hood, J ^b,d   Perrotti, D ^c   Arlinghaus, R B ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b TargeGen Inc   (United States)

^c OHIO STATE UNIVERSITY   (United States)

^d Wintherix LLC   (United States)

Author keywords

BCRABL; Drugresistance; Jak2; Lyn; PP2A; SET

Indexed keywords

BCR ABL PROTEIN; DASATINIB; FORSKOLIN; IMATINIB; JANUS KINASE 2; JANUS KINASE INHIBITOR; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; OKADAIC ACID; PHOSPHOPROTEIN PHOSPHATASE 2A; PHOSPHOPROTEIN PHOSPHATASE INHIBITOR; PROTEIN KINASE LYN; PROTEIN TYROSINE KINASE INHIBITOR; PROTEIN TYROSINE PHOSPHATASE SHP 1; SMALL INTERFERING RNA; STIBOGLUCONATE SODIUM; TG 101209; UNCLASSIFIED DRUG; 1,2,3,4,5,6 HEXABROMOCYCLOHEXANE; 1,2,3,4,5,6-HEXABROMOCYCLOHEXANE; ALPHA CYANO (3,4 DIHYDROXY) N BENZYLCINNAMIDE; ALPHA-CYANO-(3,4-DIHYDROXY)-N-BENZYLCINNAMIDE; CYCLOHEXANE DERIVATIVE; JAK2 PROTEIN, HUMAN; LYN PROTEIN-TYROSINE KINASE; NONHISTONE PROTEIN; PHOSPHOPROTEIN PHOSPHATASE 2; PIPERAZINE DERIVATIVE; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; PYRIMIDINE DERIVATIVE; SET PROTEIN, HUMAN; TRANSCRIPTION FACTOR; TYRPHOSTIN;

APOPTOSIS; ARTICLE; BLAST CELL CRISIS; CANCER CHEMOTHERAPY; CHRONIC MYELOID LEUKEMIA; ENZYME ASSAY; ENZYME INACTIVATION; FLOW CYTOMETRY; GENE MUTATION; LEUKEMIA CELL; PRIORITY JOURNAL; WESTERN BLOTTING; ANIMAL; DRUG ANTAGONISM; DRUG EFFECT; DRUG RESISTANCE; HUMAN; METABOLISM; MOUSE; PATHOLOGY; PHOSPHORYLATION; PHYSIOLOGY;

ANIMALS; APOPTOSIS; CHROMOSOMAL PROTEINS, NON-HISTONE; CYCLOHEXANES; DRUG RESISTANCE, NEOPLASM; HUMANS; JANUS KINASE 2; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MICE; PHOSPHORYLATION; PIPERAZINES; PROTEIN PHOSPHATASE 2; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 6; PROTO-ONCOGENE PROTEINS C-AKT; PYRIMIDINES; SRC-FAMILY KINASES; TRANSCRIPTION FACTORS; TYRPHOSTINS;

EID: 64949147229     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2009.7     Document Type: Article

References (35)

1. Alvarez RH, Kantarjian HM, Cortes JE. (2006). The role of Src in solid and hematologic malignancies: development of new-generation Src inhibitors. Cancer 107: 1918-1929.
2. Bruno O, Brullo C, Bondavalli F, Ranise A, Schenone S, Tognolini M et al. (2007). 2-Amino/azido/hydrazino-5-alkoxy-5H-[1]benzopyra-no[4,3-d] pyrimidines: synthesis and pharmacological evaluation. Med Chem 3: 127-134.
3. Chu S, Holtz M, Gupta M, Bhatia R. (2004). BCR/ABL kinase inhibition by imatinib mesylate enhances MAP kinase activity in chronic myelogenous leukemia CD34+ cells. Blood 103: 3167-3174.
4. Dai Y, Rahmani M, Corey SJ, Dent P, Grant S. (2004). A Bcr/Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2. J Biol Chem 279: 34227-34239.
5. Donato NJ, Wu JY, Stapley J, Gallick G, Lin H, Arlinghaus R et al. (2003). BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood 101: 690-698.
6. Donato NJ, Wu JY, Stapley J, Lin H, Arlinghaus R, Aggarwal BB et al. (2004). Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia. Cancer Res 22: 5766-5774.
7. Hu Y, Liu Y, Pelletier S, Buchdunger E, Warmuth M, Fabbro D et al. (2004). Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia. Nat Genet 36: 453-461.
8. Ilaria RL Jr, Hawley RG, Van Etten RA. (1999). Dominant negative mutants implicate STAT5 in myeloid cell proliferation and neutrophil differentiation. Blood 93: 4154-4166.
9. Kantarjian HM, Cortes JE, O'Brien S, Giles F, Garcia-Manero G, Faderl S et al. (2003). Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responses. Blood 101: 97-100.
10. Klejman A, Schreiner SJ, Nieborowska-Skorska M, Slupianek A, Wilson M, Smithgall TE et al. (2002). The Src family kinase Hck couples BCR/ABL to STAT5 activation in myeloid leukemia cells. EMBO J 21: 5766-5774.
11. Li L, Ren CH, Tahir SA, Ren C, Thompson TC. (2003). Caveolin-1 maintains activated Akt in prostate cancer cells through scaffolding domain binding site interactions with and inhibition of serine/ threonine protein phosphatases PP1 and PP2A. Mol Cell Biol 23: 9389-9404.
12. Li M, Makkinje A, Damuni Z. (1996). The myeloid leukemia-associated protein SET is a potent inhibitor of protein phosphatase 2A. J Biol Chem 271: 11059-11062.
13. Nawa M, Kanekura K, Hashimoto Y, Aiso S, Matsuoka M. (2008). A novel Akt/PKB-interacting protein promotes cell adhesion and inhibits familial amyotrophic lateral sclerosis-linked mutant SOD1- induced neuronal death via inhibition of PP2A-mediated depho-sphorylation of Akt/PKB. Cell Signal 20: 493-505.
14. Neviani P, Santhanam R, Trotta R, Notari M, Blaser BW, Liu S et al. (2005). The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein. Cancer Cell 8: 355-368.
15. Nimmanapalli R, O'Bryan E, Huang M, Bali P, Burnette PK, Loughran T et al. (2002). Molecular characterization and sensitivity of STI-571 (imatinib mesylate, Gleevec)-resistant, Bcr-Abl-positive, human acute leukemia cells to SRC kinase inhibitor PD180970 and 17-allylamino-17-demethoxygeldanamycin. Cancer Res 62: 5761-5769.
16. O'Hare T, Corbin AS, Druker BJ. (2006). Targeted CML therapy: controlling drug resistance, seeking cure. Curr Opin Genet Dev 16: 92-99.
17. Pardanani A. (2008). AK2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trials. Leukemia 22: 23-30.
18. Pardanani A, Hood J, Lasho T, Levine RL, Martin MB, Noronha G et al. (2007). TG1 01209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations. Leukemia 21: 1658-1668.
19. Pathak MK, Yi T. (2001). Sodium stibogluconate is a potent inhibitor of protein tyrosine phosphatases and augments cytokine responses in hemopoietic cell lines. J Immunol 167: 3391 - 3397.
20. Perrotti D, Neviani P. (2006). ReSETting PP2A tumour suppressor activity in blast crisis and imatinib-resistant chronic myelogenous leukaemia. Br J Cancer 95: 775-781.
21. Ptasznik A, Nakata Y, Kalota A, Emerson SG, Gewirtz AM. (2004). Short interfering RNA (siRNA) targeting the Lyn kinase induces apoptosis in primary, and drug-resistant, BCR-ABL1( + ) leukemia cells. Nat Med 10: 1187-1189.
22. Puil L, Liu J, Gish G, Mbamalu G, Bowtell D, Pelicci PG et al. (1994). Bcr-Abl oncoproteins bind directly to activators of the Ras signalling pathway. EMBO J 13: 764-773.
23. Samanta AK, Lin H, Sun T, Kantarjian H, Arlinghaus RB. (2006). Janus kinase 2: a critical target in chronic myelogenous leukemia. Cancer Res 66: 6468-6472.
24. Sandberg EM, Ma X, He K, Frank SJ, Ostrov DA, Sayeski PP. (2005). Identification of 1,2,3,4,5,6-hexabromocyclohexane as a small molecule inhibitor of jak2 tyrosine kinase autophosphoryla-tion [correction of autophophorylation]. J Med Chem 48: 2526-2533.
25. Sattler M, Mohi MG, Pride YB, Quinnan LR, Malouf NA, Podar K et al. (2002). Critical role for Gab2 in transformation by BCR/ABL. Cancer Cell 1: 479-492.
26. Weisberg E, Manley PW, Breitenstein W, Bruggen J, Cowan-Jacob SW, Ray A et al. (2005). Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 7: 129-141.
27. Wilson-Rawls J, Xie S, Liu J, Laneuville P, Arlinghaus RB. (1996). P210 Bcr-Abl interacts with the interleukin 3 receptor beta(c) subunit and constitutively induces its tyrosine phosphorylation. Cancer Res 56: 3426-3430.
28. Wong S, Witte ON. (2004). The BCR-ABL story: bench to bedside and back. Annu Rev Immunol 22: 247-306.
29. Wu J, Meng F, Lu H, Kong L, Bornmann W, Peng Z et al. (2008). Lyn regulates BCR-ABL and Gab2 tyrosine phosphorylation and c-Cbl protein stability in imatinib resistant chronic myelogenous leukemia cells. Blood 7: 3821-3829.
30. Xie S, Lin H, Sun T, Arlinghaus RB. (2002). Jak2 is involved in c-Myc induction by Bcr-Abl. Oncogene 21: 7137-7146.
31. Xie S, Wang Y, Liu J, Sun T, Wilson MB, Smithgall TE et al. (2001). Involvement of Jak2 tyrosine phosphorylation in Bcr-Abl transformation. Oncogene 20: 6188-6195.
32. Yi T, Pathak MK, Lindner DJ, Ketterer ME, Farver C, Borden EC. (2002). Anticancer activity of sodium stibogluconate in synergy with IFNs. J Immunol 169: 5978-5985.
33. Yokota A, Kimura S, Masuda S, Ashihara E, Kuroda J, Sato K et al. (2007). INNO-406, a novel BCR-ABL/Lyn dual tyrosine kinase inhibitor, suppresses the growth of Ph+ leukemia cells in the central nervous system, and cyclosporine A augments its in vivo activity. Blood 109: 306-314.
34. Yokoyama N, Reich NC, Miller WT. (2001). Involvement of protein phosphatase 2A in the interleukin-3-stimulated Jak2-Stat5 signaling pathway. J Interferon Cytokine Res 21: 369-378.
35. Yokoyama N, Reich NC, Miller WT. (2003). Determinants for the interaction between Janus kinase 2 and protein phosphatase 2A. Arch Biochem Biophys 417: 87-95.